A microfluidic device to reduce treatment time of intracytoplasmic sperm injection  

Oleh:

Matsuura, Koji ; Uozumi, Takuya

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 99 no. 02 (Feb. 2013), page 400-407.
Topik: Intracytoplasmic sperm injection; porcine sperm; ICSI treatment time; microfluidic device

Ketersediaan

Perpustakaan FK Nomor Panggil: F02.K.2013.03 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Objective To explore correlates of diminished ovarian reserve (DOR) and predictors of assisted reproductive technologies (ART) treatment outcome in DOR cycles using the Society for Assisted Reproductive Technologies-Clinical Outcomes Reporting System (SART-CORS) database; we hypothesized that mandated state insurance coverage for ART is associated with the prevalence of DOR diagnosis in ART cycles and with treatment outcomes in DOR cycles. Design Cross-sectional study using ART cycles between 2004 and 2007. Setting Not applicable. Patient(s) A total of 182,779 fresh, nondonor, initial ART cycles in women up to age 40 years. Intervention(s) None. Main Outcome Measure(s) Prevalence of DOR and elevated FSH, odds ratio of DOR and elevated FSH in ART mandated vs. nonmandated states, live birth rates. Result(s) Compared with cycles performed in states with mandated ART coverage, cycles in states with no ART mandate were more likely to have DOR (adjusted odds ratio 1.43, 95% confidence interval 1.37–1.5) or elevated FSH (adjusted odds ratio 1.69, 95% confidence interval 1.56–1.85) as the sole reason for treatment. Lack of mandated ART coverage was associated with increased live birth rates in cycles diagnosed as DOR, but not in cycles characterized only by an elevated FSH. Conclusion(s) A significant association was observed between lack of mandated insurance for ART and the proportion of cycles treating DOR or elevated FSH. The presence or absence of state-mandated ART coverage could impact access to care and the mix of patients that pursue and initiate ART cycles in ways that influence these proportions. Additional studies are needed that consider the coalescence of insurance mandates, patient and provider factors, and state-level variables on the odds of specific infertility diagnoses and treatment prognosis. Objective To develop a microfluidic device that can reduce the intracytoplasmic sperm injection (ICSI) treatment time by increasing sperm concentration. Design We compared the ICSI treatment time required for porcine sperm using a method employing the microfluidic device and one using the conventional microdroplet method. Settings Academic research laboratories at Okayama University. Animal(s) Reproductive cells of porcine sperm, oocytes, and embryos. Intervention(s) Cell manipulations, ICSI, and embryo culture. Main Outcome Measure(s) Average ICSI treatment time and sperm concentration. Result(s) The average ICSI treatment time (mean ± SEM) using the method with the microfluidic device for poor-quality semen (sperm concentration, 2.0 × 104 cells/mL) was significantly shorter than the treatment time using the conventional microdroplet method (265 ± 15 seconds [n = 43] vs. 347 ± 19 seconds [n = 50]). When diluted semen with a sperm concentration of 2.0 × 105 cells/mL was used, no significant difference was observed between the two methods (n = 50 and n = 48). Conclusion(s) The microfluidic device can reduce the time required for ICSI treatment that is used to increase sperm concentration in poor-quality semen samples. The results suggest that this device may be clinically useful for ICSI treatment in human assisted reproductive technology.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali